February 22, 2021
The Patent Trial and Appeal Board said it won't review six Allergan patents covering the company's injectable skin filler Juvederm, despite expressing skepticism toward them, after Allergan announced it has inked a licensing agreement with the low-cost rival challenging the patents.
January 12, 2021
Attorneys for Allergan had a tough time Tuesday persuading the Patent Trial and Appeal Board that six patents covering the company's injectable skin filler Juvederm are not obvious because they solved long-standing degradation problems with existing fillers, with one judge calling the argument "speculative."